Eli Lilly and Company (LLY)vsSpyre Therapeutics Inc. (SYRE)
LLY
Eli Lilly and Company
$1,131.42
-0.26%
HEALTHCARE · Cap: $948.95B
SYRE
Spyre Therapeutics Inc.
$73.65
-6.15%
HEALTHCARE · Cap: $7.02B
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SYRE
Avoid23
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Trading at 11.3x book value
0.0% revenue growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SYRE
The strongest argument for SYRE centers on Altman Z-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : SYRE
The primary concerns for SYRE are Price/Book, Revenue Growth, Profit Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while SYRE is a value play — different risk/reward profiles.
SYRE carries more volatility with a beta of 3.06 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 23/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Spyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?